nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

23.02.2016 | Original Article

[¹¹C]TASP457, a novel PET ligand for histamine H₃ receptors in human brain

verfasst von: Yasuyuki Kimura, Chie Seki, Yoko Ikoma, Masanori Ichise, Kazunori Kawamura, Keisuke Takahata, Sho Moriguchi, Tomohisa Nagashima, Tatsuya Ishii, Soichiro Kitamura, Fumitoshi Niwa, Hironobu Endo, Makiko Yamada, Makoto Higuchi, Ming-Rong Zhang, Tetsuya Suhara

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The histamine H₃ receptors are presynaptic neuroreceptors that inhibit the release of histamine and other neurotransmitters. The receptors are considered a drug target for sleep disorders and neuropsychiatric disorders with cognitive decline. We developed a novel PET ligand for the H₃ receptors, [¹¹C]TASP0410457 ([¹¹C]TASP457), with high affinity, selectivity and favorable kinetic properties in the monkey, and evaluated its kinetics and radiation safety profile for quantifying the H₃ receptors in human brain.

Methods

Ten healthy men were scanned for 120 min with a PET scanner for brain quantification and three healthy men were scanned for radiation dosimetry after injection of 386 ± 6.2 MBq and 190 ± 7.5 MBq of [¹¹C]TASP457, respectively. For brain quantification, arterial blood sampling and metabolite analysis were performed using high-performance liquid chromatography. Distribution volumes (V _T) in brain regions were determined by compartment and graphical analyses using the Logan plot and Ichise multilinear analysis (MA1). For dosimetry, radiation absorbed doses were estimated using the Medical Internal Radiation Dose scheme.

Results

[¹¹C]TASP457 PET showed high uptake (standardized uptake values in the range of about 3 – 6) in the brain and fast washout in cortical regions and slow washout in the pallidum. The two-tissue compartment model and graphical analyses estimated V _T with excellent identification using 60-min scan data (about 16 mL/cm³ in the pallidum, 9 – 14 in the basal ganglia, 6 – 9 in cortical regions, and 5 in the pons), which represents the known distribution of histamine H₃ receptors. For parametric imaging, MA1 is recommended because of minimal underestimation with small intersubject variability. The organs with the highest radiation doses were the pancreas, kidneys, and liver. The effective dose delivered by [¹¹C]TASP457 was 6.9 μSv/MBq.

Conclusion

[¹¹C]TASP457 is a useful novel PET ligand for the investigation of the density of histamine H₃ receptors in human brain.

Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H₃) of histamine receptor. Nature. 1983;302:832–7.CrossRefPubMed

Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci. 2003;4:121–30.CrossRefPubMed

Goodchild RE, Court JA, Hobson I, Piggott MA, Perry RH, Ince P, et al. Distribution of histamine H₃-receptor binding in the normal human basal ganglia: comparison with Huntington’s and Parkinson’s disease cases. Eur J Neurosci. 1999;11:449–56.CrossRefPubMed

Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H₃ receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol. 2008;154:1166–81.CrossRefPubMedPubMedCentral

Ashworth S, Rabiner EA, Gunn RN, Plisson C, Wilson AA, Comley RA, et al. Evaluation of ¹¹C-GSK189254 as a novel radioligand for the H₃ receptor in humans using PET. J Nucl Med. 2010;51:1021–9.CrossRefPubMed

Ashworth S, Berges A, Rabiner EA, Wilson AA, Comley RA, Lai RYK, et al. Unexpectedly high affinity of a novel histamine H₃ receptor antagonist, GSK239512, in vivo in human brain, determined using PET. Br J Pharmacol. 2014;171:1241–9.CrossRefPubMedPubMedCentral

Jucaite A, Takano A, Boström E, Jostell K-G, Stenkrona P, Halldin C, et al. AZD5213: a novel histamine H₃ receptor antagonist permitting high daytime and low nocturnal H₃ receptor occupancy, a PET study in human subjects. Int J Neuropsychopharmacol. 2013;16:1231–9.CrossRefPubMed

Van Laere KJ, Sanabria-Bohórquez SM, Mozley DP, Burns DH, Hamill TG, Van Hecken A, et al. ¹¹C-MK-8278 PET as a tool for pharmacodynamic brain occupancy of histamine 3 receptor inverse agonists. J Nucl Med. 2014;55:65–72.CrossRefPubMed

Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, et al. GSK189254, a novel H₃ receptor antagonist that binds to histamine H₃ receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007;321:1032–45.CrossRefPubMed

10.

Koga K, Maeda J, Tokunaga M, Hanyu M, Kawamura K, Ohmichi M, et al. Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H₃ receptors. EJNMMI Res. 2016. doi:10.1186/s13550-016-0170-2.

11.

Wardak M, Wong KP, Shao W, Dahlbom M, Kepe V, Satyamurthy N, et al. Movement correction method for human brain PET images: application to quantitative analysis of dynamic ¹⁸F-FDDNP scans. J Nucl Med. 2010;51:210–8.CrossRefPubMedPubMedCentral

12.

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.CrossRefPubMed

13.

Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–23.CrossRef

14.

Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, et al. Kinetic and equilibrium analyses of [¹²³I]epidepride binding to striatal and extrastriatal dopamine D₂ receptors. Synapse. 1999;34:290–304.CrossRefPubMed

15.

Hawkins RA, Phelps ME, Huang SC. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood–brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab. 1986;6:170–83.CrossRefPubMed

16.

Carson RE. Parameters estimation in positron emission tomography. In: Phelps ME, Mazziotta JC, Schelbert H, editors. Positron emission tomography and autoradiography: principle applications for the brain and the heart. New York: Raven Press; 1986. p. 347–90.

17.

Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-¹¹C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–7.CrossRefPubMed

18.

Logan J, Fowler JS, Volkow ND, Ding Y-S, Wang G-J, Alexoff DL. A strategy for removing the bias in the graphical analysis method. J Cereb Blood Flow Metab. 2001;21:307–20.CrossRefPubMed

19.

Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22:1271–81.CrossRefPubMed

20.

Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D₂ receptor binding with [¹²³I]epidepride SPECT. J Nucl Med. 1999;40:1902–12.PubMed

21.

Kimura Y, Ito H, Shiraishi T, Fujiwara H, Kodaka F, Takano H, et al. Biodistribution and radiation dosimetry in humans of [¹¹C]FLB 457, a positron emission tomography ligand for the extrastriatal dopamine D₂ receptor. Nucl Med Biol. 2014;41:102–5.CrossRefPubMed

22.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed

23.

Terry G, Liow J-S, Chernet E, Zoghbi SS, Phebus L, Felder CC, et al. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB₁ receptors in rodents. Neuroimage. 2008;41:690–8.CrossRefPubMedPubMedCentral

24.

Hamill TG, Sato N, Jitsuoka M, Tokita S, Sanabria S, Eng W, et al. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse. 2009;63:1122–32.CrossRefPubMed

25.

Zanotti-Fregonara P, Innis RB. Suggested pathway to assess radiation safety of ¹¹C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2012;39:544–7.CrossRefPubMed

Titel: [11C]TASP457, a novel PET ligand for histamine H3 receptors in human brain
verfasst von: Yasuyuki Kimura
Chie Seki
Yoko Ikoma
Masanori Ichise
Kazunori Kawamura
Keisuke Takahata
Sho Moriguchi
Tomohisa Nagashima
Tatsuya Ishii
Soichiro Kitamura
Fumitoshi Niwa
Hironobu Endo
Makiko Yamada
Makoto Higuchi
Ming-Rong Zhang
Tetsuya Suhara
Publikationsdatum: 23.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3332-6

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

18F-FDG PET/CT in patients with idiopathic retroperitoneal and mediastinal fibrosis

18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial

Andrew M. Evens and Kristie A. Blum (Eds), Non-Hodgkin Lymphoma. Pathology, Imaging, and Current Therapy

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm

Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle